Cargando…
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873472/ https://www.ncbi.nlm.nih.gov/pubmed/26582647 http://dx.doi.org/10.1038/leu.2015.318 |
| _version_ | 1782432883007291392 |
|---|---|
| author | Zabriskie, M S Eide, C A Yan, D Vellore, N A Pomicter, A D Savage, S L Druker, B J Deininger, M W O'Hare, T |
| author_facet | Zabriskie, M S Eide, C A Yan, D Vellore, N A Pomicter, A D Savage, S L Druker, B J Deininger, M W O'Hare, T |
| author_sort | Zabriskie, M S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4873472 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-48734722016-06-21 Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia Zabriskie, M S Eide, C A Yan, D Vellore, N A Pomicter, A D Savage, S L Druker, B J Deininger, M W O'Hare, T Leukemia Letter to the Editor Nature Publishing Group 2016-06 2015-12-08 /pmc/articles/PMC4873472/ /pubmed/26582647 http://dx.doi.org/10.1038/leu.2015.318 Text en Copyright © 2016 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Zabriskie, M S Eide, C A Yan, D Vellore, N A Pomicter, A D Savage, S L Druker, B J Deininger, M W O'Hare, T Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia |
| title | Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia |
| title_full | Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia |
| title_fullStr | Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia |
| title_full_unstemmed | Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia |
| title_short | Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia |
| title_sort | extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for bcr-abl1-positive leukemia |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873472/ https://www.ncbi.nlm.nih.gov/pubmed/26582647 http://dx.doi.org/10.1038/leu.2015.318 |
| work_keys_str_mv | AT zabriskiems extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT eideca extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT yand extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT vellorena extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT pomicterad extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT savagesl extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT drukerbj extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT deiningermw extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia AT oharet extrememutationalselectivityofaxitiniblimitsitspotentialuseasatargetedtherapeuticforbcrabl1positiveleukemia |